Will West
Plus aucun poste en cours
Historique de carrière de Will West
Anciens postes connus de Will West
Sociétés | Poste | Début | Fin |
---|---|---|---|
Odontis Ltd.
Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Corporate Officer/Principal | 20/11/2009 | 18/01/2011 |
Procter & Gamble Health & Beauty Care | Corporate Officer/Principal | - | - |
Formation de Will West
London Business School | Masters Business Admin |
Statistiques
Internationale
Royaume-Uni | 3 |
Etats-Unis | 2 |
Opérationnelle
Corporate Officer/Principal | 2 |
Masters Business Admin | 1 |
Sectorielle
Commercial Services | 2 |
Miscellaneous | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Odontis Ltd.
Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Commercial Services |
Procter & Gamble Health & Beauty Care | Miscellaneous |